OXA-type carbapenemases and susceptibility of colistin and tigecycline among carbapenem-resistant acinetobacter baumannii isolates from patients with bacteremia in Turkey

Clinical Laboratory

Volumn 61, Issue 7, 2015, Pages 741-747

  Cakirlar, Fatma Koksal ^a   Ciftci, Ihsan Hakki ^b   Gonullu, Nevriye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b SAKARYA UNIVERSITY   (Turkey)

Author keywords

Carbapenem resistant acinetobacter baumannii; Colistin; OXA type carbapenemases; Tigecycline susceptibility

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA-LACTAMASE OXA-23; BETA-LACTAMASE OXA-51, ACINETOBACTER BAUMANNII; BETA-LACTAMASE OXA-58, ACINETOBACTER BAUMANNII; CARBAPENEMASE; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIUM ISOLATE; BLOOD CULTURE; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; DISK DIFFUSION; EPSILOMETER TEST; FEMALE; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIC50; MIC90; OXA 23 GENE; OXA 51 GENE; OXA 58 GENE; REAL TIME POLYMERASE CHAIN REACTION; TURKEY (REPUBLIC); ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HOSPITAL PATIENT; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; TURKEY; UNIVERSITY HOSPITAL;

ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; HOSPITALS, UNIVERSITY; HUMANS; INPATIENTS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; MULTIPLEX POLYMERASE CHAIN REACTION; TURKEY;

EID: 84938685127     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.141116     Document Type: Article

References (39)

1. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005;11:868-73.
2. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692-9.
3. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. International Journal of Antimicrobial Agents 2012; 39:105-14.
4. Paton R, Miles RS, Hood J, et al. ARI 1: β-lactam ase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993;2(2):81-7.
5. Hornsey M, Ellington MJ, Doumith M, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010;65:1589-93.
6. Dhabaan GN, AbuBakar S, Shorman MA, Hassan H. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia. J Chemother 2012;24:87- 92.
7. Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110-6.
8. Deng M, Zhu MH, Li JJ, et al. Molecular Epidemiology and Mechanisms of Tigecycline Resistance in Clinical Isolates of Acinetobacter baumannii from a Chinese University Hospital. Antimicrobial Agents and Chemotherapy 2014;58: 297-303.
9. Poirel L, Naas T, Nordmann P. Diversity, epidemiology and genetics of class D β-lactamases. Antimicrobial Agents and Chemotherapy 2010;54:24-38.
10. Lean SS, Suhaili Z, Ismail S, et al. Prevalence and Genetic Characterization of Carbapenem- And Polymyxin-Resistant Acinetobacter baumannii Isolated from a Tertiary Hospital in Terengga- nu, Malaysia. Hindawi Publishing Corporation, ISRN Microbiology Volume 2014, Article ID 953417, 9 pages, 2014. http://dx.doi.org/10.1155/2014/953417.
11. Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY. Carbapenem Resistance in Acinetobacter baumannii, Laboratory Challenges, Mechanistic Insights and Therapeutic Strategies. Expert Rev Anti Infect Ther 2013;11(4):395-409.
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI Document M100-S24. 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2014.
13. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org/antimicrobial-susceptibility-testing/.
14. Food and Drug Administration (FDA). FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. U.S. Food and Drug Administration, Silver Spring, Rockville, MD, 2010. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
15. Ciftci IH, Asik G, Karakece E, et al. Antibiotic Resistance Mechanisms of Acinetobacter baumannii. Mikrobiyol Bui 2013;47(4): 592-602.
16. Woodford N, Ellington MJ, Coelho JM, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. International Journal of Antimicrobial Agents 2006;27:351- 3.
17. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagnost Microbiol Infect Dis 2004;50(1):59-69.
18. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden, ECDC; 2013.
19. Centers for Disease Control and Prevention (CDC) Antibiotic resistance threats in the United States, 2013. U.S. Department of Health and Human Services, 2013. http://www.cdc.gov/drugresis-tance/threat-report-2013/pdfarthreats-2013-508.pdf.
20. National nosocomial infections surveillance network (UHESA) report, Summary data. Republic of Turkey, Ministry of Health, General Directorate of Health Services, Department of Health Service Standards, 2012. http://uhes.saglik.gov.tr/public/indir/uhesa%20anal%C4%B0z-2012.pdf.
21. Noskin GA. Tigecycline: A New Glycylcycline for Treatment of Serious Infections. Clin Infect Dis 2005;41:303-14.
22. Giannouli M, Cuccurullo S, Crivaro V, et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone. Journal of Clinical Microbiology 2010;48(4):1223- 30.
23. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY Antimicrobial Surveil-lance Program (2006-09). J Antimicrob Chemother 2011;66: 2070-4.
24. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. Journal of Antimicrobial Chemotherapy 2012;67 (7):1607-15.
25. Wieczorek P, Sacha P, Hauschild T, et al. Multidrug resistant Acinetobacter baumannii-the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol 2008;46(3):257-67.
26. Wyeth Pharmaceuticals. Tygacil (Package Insert), Wyeth Pharmaceuticals Inc., Philadelphia, PA. USA, 2010.
27. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008; 13(47): 1 -11.
28. Dizbay M, Altuncekic A, Sezer BE, et al. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32(1):29-32.
29. Ergin A, Hascelik G, Eser OK. Molecular characterization of ox- Acillinases and genotyping of invasive Acinetobacter baumannii isolates using repetitive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010. Scandinavian Journal oflnfectious Diseases 2013;45(1):26-31.
30. Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two component systems. Antimicrob Agents Chemother 2009;53:3628-34.
31. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipo- polysaccharide production. Antimicrob Agents Chemother 2010; 54:4971-7.
32. Eser OK, Ergin A, Hascelik G. Antimicrobial resistance and existence of metallo-b-lactamase in Acinetobacter species isolated from adult patients. Mikrobiyol Bui 2009;43:383-90.
33. Park YK, In Jung S, Park KH, et al. Changes in antimicrobial susceptibility and major clones of Acinetobacter calcoaceticus-bau- mannii complex isolates from a single hospital in Korea over 7 years. Journal of Medical Microbiology 2012;61:71-9.
34. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA beta-Iactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000;44:196-9.
35. Vahaboglu H, Budak F, Kasap M, et al. High prevalence of OXA-51-type class D/β-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006;58:537-42.
36. Meric M, Kasap M, Gacar G, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Turkey . FEMS Microbiol Lett 2008;282:214-8.
37. Poirel I, Marque S, Heritier C, et al. OXA-58, a novel class D-lac-tamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:202-8.
38. Gur D, Korten V, Unal S, et al. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-produc ing Acinetobacter baumannii: Report from the Turkish SENTRY Program sites. Journal of Medical Microbiology 2008;57, 1529-32.
39. Kulah, C, Mooij MJ, Comert F, et al. Characterisation of carba- penem-resistant Acinetobacter baumannii outbreak strains producing OXA-58 in Turkey. Int J Antimicrob Agents 2010;36, 114- 8.